Table A1.
Univariate Cox Proportional Hazards Regression Analysis
| Predictor | HR | 95% CI | P |
|---|---|---|---|
| Age (> 60 v ≤ 60 years) | 0.88 | 0.66 to 1.16 | .351 |
| Sex (male v female) | 1.44 | 1.06 to 1.96 | .018 |
| Race (white v nonwhite) | 0.75 | 0.56 to 1.00 | .051 |
| Hepatitis virus infection status | |||
| No infection v HBV + HCV | 0.51 | 0.32 to 0.80 | .004 |
| HBV alone v HBV + HCV | 0.76 | 0.44 to 1.32 | .334 |
| HCV alone v HBV + HCV | 0.72 | 0.43 to 1.18 | .192 |
| Serum AFP level (≥ 400 v < 400 ng/mL) | 2.26 | 1.69 to 3.02 | < .001 |
| Tumor differentiation (poor v other) | 1.63 | 1.15 to 2.31 | .006 |
| Tumor nodularity (multinodular v uninodular) | 2.28 | 1.68 to 3.11 | < .001 |
| Tumor size (> 50% v ≤ 50% of liver) | 2.92 | 2.19 to 3.90 | < .001 |
| Vascular invasion (yes v no) | 2.65 | 1.90 to 3.70 | < .001 |
| Lymph node involvement (yes v no) | 1.82 | 1.38 to 2.40 | < .001 |
| Metastasis (yes v no) | 1.76 | 1.27 to 2.45 | .001 |
| Bilirubin level (> 1.6 v ≤ 1.6 mg/dL) | 2.74 | 1.78 to 4.22 | < .001 |
| Serum ALT level (> 40 v ≤ 40 U/L) | 1.77 | 1.34 to 2.34 | < .001 |
| Serum AST level (> 45 v ≤ 45 U/L) | 2.17 | 1.57 to 3.00 | < .001 |
| Cirrhosis (yes v no) | 1.35 | 1.02 to 1.79 | .036 |
| Treatment | |||
| Chemotherapy v none | 0.56 | 0.38 to 0.84 | .0047 |
| Surgery v none | 0.19 | 0.12 to 0.31 | < .001 |
| Chemoembolization v none | 0.38 | 0.22 to 0.67 | < .001 |
| IGF-1 (≤ 26 v > 26 ng/mL) | 2.06 | 1.5 to 2.81 | < .001 |
| VEGF (> 450 v ≤ 450 pg/mL) | 1.74 | 1.26 to 2.43 | < .001 |